Selected model input parameters, including transition probabilities, costs, and utilities
| Inputs: outcome probabilities . | Base case . | Sensitivity analysis range . | Monte Carlo distribution . | References . |
|---|---|---|---|---|
| Therapies in the second-line setting | ||||
| axi-cel | ||||
| Overall outcomes | ||||
| EFS rate at 2 y | 0.41 | 0.35-0.52 | β | 5 |
| OS rate at 2 y | 0.61 | 0.45-0.78 | β | 5 |
| Progression-free survival rate at 2 y | 0.46 | 0.37-0.67 | β | 5 |
| Adverse events | ||||
| CRS (any grade) | 0.92 | 0.7-1.1 | β | 5 |
| CRS (grade ≥3) | 0.06 | 0.03-0.1 | β | 5 |
| SOC | ||||
| Overall outcomes | ||||
| EFS rate at 2 y | 0.16 | 0.10-0.21 | β | 5 |
| OS rate at 2 y | 0.52 | 0.38-0.73 | β | 5 |
| Progression-free survival rate at 2 y | 0.27 | 0.12-0.42 | β | 5 |
| Salvage chemoimmunotherapy | ||||
| CR after salvage | 0.32 | 0.2-0.5 | β | 17 |
| PR after salvage | 0.18 | 0.05-0.3 | β | 17 |
| Stable disease after salvage | 0.18 | 0.05-0.3 | β | 17 |
| auto-SCT | ||||
| Receipt of transplantation after CR with salvage | 0.80 | 0.70-0.94 | β | 17 |
| Receipt of transplantation after PR with salvage | 0.54 | 0.58-0.78 | β | 17 |
| OS rate after CR + SCT after 1 y | 0.83 | 0.70-0.97 | β | 17 |
| OS rate after PR + SCT after 1 y | 0.59 | 0.45-0.72 | β | 17 |
| Adverse events | ||||
| Febrile neutropenia (grade ≥3) | 0.27 | 0.1-0.5 | β | 5 |
| Anemia requiring blood transfusion (grade ≥3) | 0.39 | 0.1-0.6 | β | 5 |
| Leukopenia (grade ≥3) | 0.22 | 0.05-0.9 | β | 5 |
| Therapies in the third-line setting | ||||
| axi-cel | ||||
| CR after CAR-T | 0.58 | 0.49-0.67 | β | 2 |
| PR after CAR-T | 0.24 | 0.17-0.33 | β | 2 |
| OS rate after 4 y | 0.44 | 0.34-0.54 | β | 2 |
| EFS after 2 y | 0.38 | 0.31-0.41 | β | 2 |
| Salvage chemoimmunotherapy + auto-SCT (after second-line CAR-T) | ||||
| Overall response rate | 0.30 | 0.1 – 0.5 | β | 1,20 |
| Receipt of transplantation after CR with salvage | 0.30 | 0.2-0.6 | β | Expert opinion |
| Receipt of transplantation after PR with salvage | 0.10 | 0.05-0.3 | β | Expert opinion |
| Costs | ||||
| Inputs: Costs, 2021 US dollars | ||||
| Pharmaceutical | ||||
| Salvage chemoimmunotherapy | 20 762 | 20 000-100 000 | γ | 21 |
| axi-cel | 393 104 | 200 000-700 000 | γ | 22 |
| Administration and adverse events | ||||
| Salvage chemoimmunotherapy | 14 649 | 14 000-44 000 | γ | 21,23 |
| axi-cel | 59 124 | 35 000-70 000 | γ | 21,23 |
| auto-SCT | 139 194 | 70 000-190 000 | γ | 23,24 |
| Utilities | ||||
| Inputs: utilities, QALYs | ||||
| RR-DLBCL | 0.63 | 0.3-0.8 | β | 25 |
| auto-SCT therapy (2 mo) | 0.43 | 0.2-0.6 | β | 26 |
| CAR-T (2 mo) | 0.50 | 0.3-0.7 | β | 26 |
| Remission after CAR-T | 0.70 | 0.6-0.9 | β | 26 |
| Progression after CAR-T | 0.45 | 0.1-0.6 | β | 26 |
| Inputs: outcome probabilities . | Base case . | Sensitivity analysis range . | Monte Carlo distribution . | References . |
|---|---|---|---|---|
| Therapies in the second-line setting | ||||
| axi-cel | ||||
| Overall outcomes | ||||
| EFS rate at 2 y | 0.41 | 0.35-0.52 | β | 5 |
| OS rate at 2 y | 0.61 | 0.45-0.78 | β | 5 |
| Progression-free survival rate at 2 y | 0.46 | 0.37-0.67 | β | 5 |
| Adverse events | ||||
| CRS (any grade) | 0.92 | 0.7-1.1 | β | 5 |
| CRS (grade ≥3) | 0.06 | 0.03-0.1 | β | 5 |
| SOC | ||||
| Overall outcomes | ||||
| EFS rate at 2 y | 0.16 | 0.10-0.21 | β | 5 |
| OS rate at 2 y | 0.52 | 0.38-0.73 | β | 5 |
| Progression-free survival rate at 2 y | 0.27 | 0.12-0.42 | β | 5 |
| Salvage chemoimmunotherapy | ||||
| CR after salvage | 0.32 | 0.2-0.5 | β | 17 |
| PR after salvage | 0.18 | 0.05-0.3 | β | 17 |
| Stable disease after salvage | 0.18 | 0.05-0.3 | β | 17 |
| auto-SCT | ||||
| Receipt of transplantation after CR with salvage | 0.80 | 0.70-0.94 | β | 17 |
| Receipt of transplantation after PR with salvage | 0.54 | 0.58-0.78 | β | 17 |
| OS rate after CR + SCT after 1 y | 0.83 | 0.70-0.97 | β | 17 |
| OS rate after PR + SCT after 1 y | 0.59 | 0.45-0.72 | β | 17 |
| Adverse events | ||||
| Febrile neutropenia (grade ≥3) | 0.27 | 0.1-0.5 | β | 5 |
| Anemia requiring blood transfusion (grade ≥3) | 0.39 | 0.1-0.6 | β | 5 |
| Leukopenia (grade ≥3) | 0.22 | 0.05-0.9 | β | 5 |
| Therapies in the third-line setting | ||||
| axi-cel | ||||
| CR after CAR-T | 0.58 | 0.49-0.67 | β | 2 |
| PR after CAR-T | 0.24 | 0.17-0.33 | β | 2 |
| OS rate after 4 y | 0.44 | 0.34-0.54 | β | 2 |
| EFS after 2 y | 0.38 | 0.31-0.41 | β | 2 |
| Salvage chemoimmunotherapy + auto-SCT (after second-line CAR-T) | ||||
| Overall response rate | 0.30 | 0.1 – 0.5 | β | 1,20 |
| Receipt of transplantation after CR with salvage | 0.30 | 0.2-0.6 | β | Expert opinion |
| Receipt of transplantation after PR with salvage | 0.10 | 0.05-0.3 | β | Expert opinion |
| Costs | ||||
| Inputs: Costs, 2021 US dollars | ||||
| Pharmaceutical | ||||
| Salvage chemoimmunotherapy | 20 762 | 20 000-100 000 | γ | 21 |
| axi-cel | 393 104 | 200 000-700 000 | γ | 22 |
| Administration and adverse events | ||||
| Salvage chemoimmunotherapy | 14 649 | 14 000-44 000 | γ | 21,23 |
| axi-cel | 59 124 | 35 000-70 000 | γ | 21,23 |
| auto-SCT | 139 194 | 70 000-190 000 | γ | 23,24 |
| Utilities | ||||
| Inputs: utilities, QALYs | ||||
| RR-DLBCL | 0.63 | 0.3-0.8 | β | 25 |
| auto-SCT therapy (2 mo) | 0.43 | 0.2-0.6 | β | 26 |
| CAR-T (2 mo) | 0.50 | 0.3-0.7 | β | 26 |
| Remission after CAR-T | 0.70 | 0.6-0.9 | β | 26 |
| Progression after CAR-T | 0.45 | 0.1-0.6 | β | 26 |
CR, complete response; PR, partial response.